Wang, Y., Zhou, Y., Jia, G., Han, B., Liu, J., Teng, Y., Lv, J., Song, Z., Li, Y., Ji, L., Pan, S., Jiang, H. and Sun, B. (2014) Shikonin Suppresses Tumour Growth and Synergizes with Gemcitabine in a Pancreatic Cancer Xenograft Model: Involvement of NF-κB Signalling Pathway. Biochemical Pharmacology, 88, 322-333.
https://doi.org/10.1016/j.bcp.2014.01.041

has been cited by the following article:

• TITLE: Acetylshikonin Inhibits Colorectal Cancer Growth via PI3K/Akt/mTOR Signaling Pathway

  AUTHORS: Yuzhen Zhu, Yu Zhong, Yu Zhou, Yanyan Liu, Qionglin Huang, Zhe Huang, Yongcun Wang, Hua Ye, Xiaobing Zeng, Xuebao Zheng

  KEYWORDS: Arnebia euchroma, Acetylshikonin, Colorectal Cancer, Apoptosis, PI3K/Akt/mTOR Pathway

  JOURNAL NAME: Chinese Medicine, Vol.9 No.3, August 8, 2018

  ABSTRACT: Background: Acetylshikonin, a major constituent isolated from Arnebia euchroma, is a potential candidate for anti-colorectal cancer drugs. However, the potential activity and underlying mechanism of Acetylshikonin against colorectal cancer remain unclear. Methods: In this study, Acetylshikonin was isolated from the active CHCl3 extract of Arnebia euchroma using activity-guided screening, and elucidated by the extensive spectroscopic analysis and comparison with literature data. Human colorectal cancer cells HT29, DLD-1, HCT116 or Caco-2 were exposed to different concentrations of Acetylshikonin (6.25 - 100 μg/mL) for 24 or 48 h. Cell viability, cell apoptosis and cell cycle distribution were detected. The activity of Acetylshikonin and potential mechanism of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway were evaluated in vitro and vivo. Results: We found that Acetylshikonin exhibited remarkable anti-proliferative activity in a dose-dependent manner against HT29 cells with the IC50 values of 60.82 μg/ml and 30.78 μg/ml at 24, 48 h, respectively. Moreover, Acetylshikonin induced cell cycle arrest at G0/G1 phase and early apoptosis through inhibition of PI3K/Akt/mTOR pathway. Furthermore, the assays of cell inhibition, early apoptosis and G0/G1 phase distribution showed that suppression of the PI3K/Akt pathway using LY294002 enhanced the anti-cancer effect of Acetylshikonin. Similarly, Acetylshikonin also decreased the growth of tumour in colorectal cancer xenografts in mice through PI3K/Akt/mTOR pathway. Conclusions: To sum up, these new findings provided a framework for further exploration of Acetylshikonin which possessed the potential antitumor activity by inhibiting PI3K/Akt/mTOR pathway.